BOLT - Company ID 0001641281
The table below shows Bolt Biotherapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.02M | -$13.37M | -$16.75M | -$23.40M | -$24.31M | -$16.56M |
| Capital expenditure | - | - | $0.00 | $3.00K | $605.00K | $58.00K |
| Investing cash flow | $7.92M | $14.55M | $10.20M | $28.99M | $40.84M | -$190.52M |
| Dividends paid | - | - | - | - |
Bolt Biotherapeutics, Inc. reported operating cash flow of -$39.85M for fiscal year 2025. That is up 35.0% from -$61.29M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$47.31M (FY 2020) to -$39.85M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $6.00K | $0.00 | $0.00 | - | $107.00K | $297.02M |